A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.

NCT ID: NCT00330460

Last Updated: 2011-01-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 1189 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-05-31
• Study Completion Date: 2008-01-31

Brief Summary

The purpose of this study is to determine whether in postmenopausal women with low bone mineral density, the mean percent change in total hip BMD in subjects receiving denosumab is not less than that observed in subjects receiving alendronate sodium by more than a pre-specified non-inferiority margin.

Conditions

Osteoporosis; Osteopenia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Alendronate

Subjects in this arm will receive active ALN and placebo denosumab

Group Type: ACTIVE_COMPARATOR

Alendronate

Intervention Type: DRUG

ALN; 70 mg; oral; once weekly

Denosumab

Subjects in this arm will receive active denosumab and placbo ALN

Group Type: EXPERIMENTAL

Denosumab

Intervention Type: DRUG

60 mg; SC; every 6 months

Interventions

Alendronate

ALN; 70 mg; oral; once weekly

Intervention Type: DRUG

Denosumab

60 mg; SC; every 6 months

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Evidence of any of the following per subject report, chart review or central laboratory result:

1. Hyper- or hypothyroidism; however, subjects on stable thyroid hormone replacement therapy may be allowed per the following criteria:

• If TSH level is normal, subject is eligible for the study.
• If TSH level is below normal range, subject is not eligible for the study.
• If TSH level is elevated (> 5.5 mIU/mL to 10.0 mIU/mL), serum T4 should be measured. If serum T4 is within normal range, subject is eligible. If serum T4 is outside of normal range, subject is not eligible for the study.
• If TSH level is above 10.0 mIU/mL, subject is not eligible.

2. Current hyper- or hypoparathyroidism

3. Elevated transaminases

• Serum aspartate aminotransferase (AST; serum glutamate-oxaloacetic transaminase [SGOT]) ³ 2.0 x upper limits of normal (ULN)
• Serum alanine aminotransferase (ALT; serum glutamate-pyruvate transaminase [SGPT]) ³ 2.0 x ULN

4. Significantly impaired renal function as determined by serum creatinine ³ 2.0 mg/dL

5. Current hypo- or hypercalcemia based on the central laboratory reference ranges

6. Active gastric or duodenal ulcer; history of significant gastrointestinal bleed requiring hospitalization or transfusion, or dyspepsia or gastroesophageal reflux disease that is uncontrolled by medication

7. Rheumatoid Arthritis, Paget's disease, Cushing's disease, hyperprolactinemia, or cirrhosis of the liver

8. Known to have tested positive for human immunodeficiency virus, hepatitis C virus, or hepatitis B surface antigen

9. Malignancy (except fully resected cutaneous basal cell or squamous cell carcinoma, cervical or breast ductal carcinoma in situ) within the last 5 years

10. Any metabolic bone disease, eg, osteomalacia or osteogenesis imperfecta, which may interfere with the interpretation of the findings

11. Malabsorption syndrome or any gastrointestinal disorders that are associated with malabsorption

• Received any solid organ or bone marrow transplant
• Vitamin D deficiency (25(OH) vitamin D level < 12 ng/mL). Vitamin D repletion will be permitted and subjects may be re-screened; see Section 7.
• Any laboratory abnormality which, in the opinion of the investigator, will prevent the subject from completing the study or interfere with the interpretation of the study results
• Contraindicated or poorly tolerant of ALN therapy; contraindications for ALN therapy include:

1. Abnormalities of the esophagus, which delay esophageal emptying such as stricture or achalasia.

2. Inability to stand or sit upright for at least 30 minutes.

3. Hypersensitivity to ALN or other constituents of ALN tablets o Known sensitivity to mammalian cell derived drug products

• Known intolerance to calcium supplements
• Administration of intravenous bisphosphonate, or fluoride (except for dental treatment) or strontium ranelate
• Oral bisphosphonate treatment:

• ³ 3 months cumulatively in the past 2 years, OR
• ³ 1 month in the past year, OR
• Any use during the 3-month period prior to randomization
• PTH or PTH derivatives (eg, teriparatide) within the last year
• Administration of any of the following treatments within 3 months of randomization:

1. Any SERM (eg, raloxifene)

2. Tibolone

3. Anabolic steroids or testosterone

4. Glucocorticosteroids (³ 5 mg prednisone equivalent per day for more than 10 days)

5. Systemic (oral, transdermal, topical) hormone replacement therapy (local vaginal estrogen preparation will be allowed)

6. Calcitonin

7. Calcitriol or vitamin D derivatives

8. Other bone active drugs including anti-convulsives (except benzodiazepines) and heparin

9. Chronic systemic ketoconazole, androgens, ACTH, cinacalcet, aluminum, lithium, protease inhibitors, methotrexate, gonadotropin-releasing hormone agonists

10. Height, weight or girth which may preclude accurate DXA measurements

• Less than 2 lumbar vertebrae (L1-L4) evaluable for DXA measurements
• Both hips not evaluable by DXA (eg, history of bilateral hip replacement or pins in both hips)
• Currently enrolled in or has not yet completed at least 1 month since ending other investigational device or drug trial(s), or subject is receiving other investigational agent(s)
• Any physical or psychiatric disorder which, in the opinion of the investigator, will prevent the subject from completing the study or interfere with the interpretation of the study results
• Evidence of alcohol or substance-abuse within the last 12 months which the investigator believes would interfere with understanding or completing the study

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Amgen

INDUSTRY

Sponsor Role: lead

Responsible Party

Amgen Inc.

Principal Investigators

MD

Role: STUDY_DIRECTOR

Amgen

References

Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, Alvaro-Gracia JM, Wang H, Austin M, Wagman RB, Newmark R, Libanati C, San Martin J, Bone HG. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009 Jan;24(1):153-61. doi: 10.1359/jbmr.0809010.

Reference Type: RESULT

PMID: 18767928 (View on PubMed)

Gold DT, Horne R, Coon CD, Price MA, Borenstein J, Varon SF, Satram-Hoang S, Macarios D. Development, reliability, and validity of a new Preference and Satisfaction Questionnaire. Value Health. 2011 Dec;14(8):1109-16. doi: 10.1016/j.jval.2011.06.010. Epub 2011 Oct 1.

Reference Type: DERIVED

PMID: 22152181 (View on PubMed)

Related Links

http://www.amgentrials.com

AmgenTrials clinical trials website

http://download.veritasmedicine.com/REGFILES/amgen/Amgen_results_disclaimer.pdf

Notice regarding posted summaries of trial results

http://download.veritasmedicine.com/REGFILES/amgen/08D_FDAMA_113_Posting_Summary_49_AMG_162_20050141.pdf

To access clinical trial results information click on this link

Other Identifiers

20050141

Identifier Type: -

Identifier Source: org_study_id